|1.||Emionite, Laura: 2 articles (02/2005 - 11/2004)|
|2.||Toma, Salvatore: 2 articles (02/2005 - 11/2004)|
|3.||Scarabelli, Linda: 1 article (02/2005)|
|4.||Ravera, Giambattista: 1 article (02/2005)|
|5.||Scaramuccia, Angelo: 1 article (02/2005)|
|6.||Vergani, Laura: 1 article (11/2004)|
|7.||Boccardo, Francesco: 1 article (11/2004)|
|8.||Galmozzi, Fabia: 1 article (11/2004)|
|9.||Grattarola, Myriam: 1 article (11/2004)|
|1.||Breast Neoplasms (Breast Cancer)
02/28/2005 - "The data obtained in this study represents the basis for a further evaluation of Ro 41-5253 anti-neoplastic activity on transgenic breast cancer animal models."
09/25/1998 - "RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines."
02/28/2005 - "The aim of the present study was to evaluate the in vivo effects of the RAR-alpha selective antagonist Ro 41-5253 on a xenograft animal model for breast cancer. "
11/01/2004 - "We analysed the anti-proliferative activity of two histone-deacetylase inhibitors (HDACIs), Trichostatin A (TSA) and sodium phenylbutyrate (PB), alone or combined with retinoids, all-trans retinoic acid (ATRA) and Ro 41-5253, on two human breast cancer cell lines: the hormone-dependent MCF-7 and the hormone-independent MDA-MB-231. "
|2.||Lung Neoplasms (Lung Cancer)
|1.||retinoic acid receptor alpha
|2.||Histone Deacetylase Inhibitors
|3.||Tretinoin (Retinoic Acid)
|7.||trichostatin A (A 300)
|1.||Heterologous Transplantation (Xenotransplantation)